{"id":"gt20029-tincture","_chembl":{"chemblId":"CHEMBL2108495","moleculeType":"Unknown"},"modality":"Small molecule","_dailymed":null,"mechanism":{"target":"Androgen receptor","explanation":"GT20029 is designed as a topical androgen receptor antagonist that may block the effects of dihydrotestosterone (DHT) on hair follicles. By inhibiting androgen receptor signaling locally in the scalp, it aims to prevent hair follicle miniaturization and promote hair regrowth without systemic hormonal effects.","oneSentence":"GT20029 is believed to target androgen receptor pathways involved in hair follicle miniaturization."},"_scrapedAt":"2026-03-28T04:01:24.454Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123891,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"minoxidil","brand":"Rogaine","company":null,"rationale":"Topical treatment for androgenetic alopecia, current standard of care"},{"name":"finasteride","brand":"Propecia","company":"Merck","rationale":"5-alpha reductase inhibitor for male pattern hair loss"},{"name":"pyrilutamide","brand":null,"company":"Kintor Pharmaceutical","rationale":"Topical androgen receptor antagonist in development for alopecia"}],"description":"GT20029 is an investigational topical tincture developed by Suzhou Kintor Pharmaceutical for the treatment of hair loss conditions. Currently in Phase 2 clinical development, it represents a novel approach to androgenetic alopecia treatment through a targeted mechanism.","indications":{"approved":[{"status":"investigational","condition":"Androgenetic alopecia","patientPopulation":"Adult male and female patients"}]},"trialDetails":[{"nctId":"NCT06692465","phase":"PHASE2","title":"To Evaluate the Efficacy and Safety of GT20029 Solution in the Treatment of Androgenetic Alopecia (AGA) in Chinese Adult Males","status":"COMPLETED","sponsor":"Suzhou Kintor Pharmaceutical Inc,","startDate":"2023-04-13","conditions":"Alopecia, Male Pattern Hair Loss","enrollment":180}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"GT20029 Tincture","genericName":"GT20029 Tincture","companyName":"Suzhou Kintor Pharmaceutical Inc,","companyId":"suzhou-kintor-pharmaceutical-inc","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}